B+
Bull case
25%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
PEPG
PepGenFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The stock is depressed versus its prior biotech valuation range, the 5 mg/kg FREEDOM2 data were clean on safety, ex-U.S. enrollment/dosing continues despite the U.S.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
10 mg/kg FREEDOM2 data may fail to show clearly improved splicing or functional benefit versus the 5 mg/kg cohort.
Momentum
97
Value
41
Sentiment
5
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $3.40 · Bear $0.60Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $10.19
Why
Momentum97 · Δ7d +0.6
Value41 · Δ7d 0.0
Sentiment5 · Δ7d +0.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • 10 mg/kg FREEDOM2 data may fail to show clearly improved splicing or functional benefit versus the 5 mg/kg cohort.
- • Cash runway extends into 2H 2027, but a delayed or disappointing readout could still force dilutive financing before any major de-risking.
- • This remains a low-coverage, clinical-stage story with a U.S.
Catalyst clock
2026-09-30
FDA partial clinical hold resolution remains the key swing factor
Lead driver: Value · See fundamentals
Momentum
97
9% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+6.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
5
62% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
-4.5
Why this grade
Composite grade F. Momentum 97.1 / Value 41.2 / Sentiment 5.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.60
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$210.55M
Beta
1.92
Shares Out
69.26M
P/E (TTM) · Derived
-1.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.36
Rev YoY
-
EPS YoY
-63.5%
Gross Margin
-
Op Margin
-
Net Debt
-$131.45M
Current Ratio
13.36
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data